Table 2 Characteristics of the 218 HIV-TB co-infected patients divided by initiation timing of HAART*
From: The impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort study
| Â | HAART initiation timing during anti-TB therapy | ||||
|---|---|---|---|---|---|
|  | No HAART (n = 36) | 0–15 days (n = 110) | 16–30 days (n = 34) | 31–60 days (n = 19) | >60 days (n = 19) |
Age (yrs) at first TB diagnosis, median [IQR] | 38.8 [32.0–49.6] | 36.8 [31.8–43.6] | 35.5 [31.2–46.7] | 36.6 [33.7–45.1] | 40.4 [29.5–61.3] |
Male | 31 (86.1%) | 107 (97.3%) | 33 (97.1%) | 18 (94.7%) | 17 (89.5%) |
Female | 5 (13.9%) | 3 (2.7%) | 1 (2.9%) | 1 (5.3%) | 2 (10.5%) |
CD4 count(/mm3) at TB diagnosis, median [IQR]$ | 69 [17–370] | 37 [16–87] | 34 [14–62] | 68 [23–134] | 36 [17–94] |
  ≤50 | 14 (38.9%) | 68 (62.4%) | 26 (74.3%) | 8 (42.15%) | 11 (57.9%) |
  51–100 | 7 (19.4%) | 18 (16.4%) | 2 (5.9%) | 5 (26.3%) | 4 (21.1%) |
  101–200 | 5 (13.9%) | 11 (10.1%) | 3 (8.6%) | 4 (21.1%) | 1 (5.3%) |
  ≥200 | 10 (30.8%) | 13 (11.9%) | 3 (8.6%) | 2 (10.5%) | 3 (15.8%) |
Localization of tuberculosis | Â | Â | Â | Â | Â |
  Pulmonary | 16 (44.4%) | 31 (28.5%) | 15 (42.9%) | 6 (31.6%) | 7 (36.8%) |
  PTB+ extra-pulmonary | 19 (52.8%) | 72 (65.5%) | 19 (55.9%) | 6 (31.6%) | 12 (63.2%) |
  Extra-pulmonary | 1 (2.8%) | 7 (6.4%) | 0 | 7 (36.8%) | 0 |
Laboratory findings | Â | Â | Â | Â | Â |
  Positive AFS smear ± positive MTB Culture | 27 (75.0%) | 85 (78.0%) | 29 (82.9%) | 13 (68.4%) | 12 (63.2%) |
  Positive MTB culture only | 9(25.0%) | 25(22.7%) | 5(14.7%) | 6(31.6%) | 7(36.8%) |
HBV(+)#$ | 6(16.7%) | 22(20.2%) | 1(2.9%) | 4(21.1%) | 3(15.8%) |
HCV(+)#$ | 9(25.0%) | 11(10.1%) | 3(8.6%) | 1(5.3%) | 1(5.3%) |
IRIS$ | – | 41(37.3%) | 12(35.3%) | 2(10.5%) | 2(10.5%) |
Death$ | 23(63.9%) | 19(17.3%) | 5(14.7%) | 0 | 5(26.3%) |
TB-related death$ | 19(52.8%) | 15(13.6%) | 2(5.9%) | 0 | 3(15.8%) |